Isolated sulfite oxidase deficiency is an ultra-rare neurometabolic disorder caused by biallelic pathogenic variants in the SUOX gene. It is inherited in an autosomal recessive manner and is due to the loss or reduction of enzyme activity, which prevents the transformation of sulfite into sulfate and causes the accumulation of neurotoxic metabolites.
Isolated sulfite oxidase deficiency
The SUOX gene encodes a mitochondrial intermembrane space molybdoprotein. Sulfite oxidase converts sulfite to sulfate in the final step of cysteine and methionine degradation.
Pathogenic variants favor the accumulation of sulfite, thiosulfate, and S-sulfocysteine, which alter energy metabolism and can induce neuronal excitotoxicity. The spectrum ranges from severe neonatal encephalopathy to attenuated late-onset forms. The exact prevalence is unknown and underdiagnosis likely exists. It has been described in various populations, with possible increased frequency in consanguineous communities, without a universally recognized founder variant.
Symptoms
The classic form begins in the first hours or days of life with refractory epileptic seizures, feeding problems, and progressive encephalopathy. Tone alterations, opisthotonos, spasticity, microcephaly, and profound intellectual disability are frequent. Neuroimaging can simulate a hypoxic-ischemic injury and progress to atrophy and cystic encephalomalacia. Lenticular ectopia usually appears after the neonatal period. Late forms present with developmental delay or regression, dystonia, choreoathetosis, ataxia, episodes of encephalopathy, or, rarely, metabolic stroke. The course can be progressive or episodic, and ocular involvement is variable.
Disease management
There is no curative treatment or approved disease-modifying therapy. Multidisciplinary management includes control of seizures and spasticity, physiotherapy, nutritional support, and gastrostomy when dysphagia or risk of aspiration is present. Respiratory complications, hypoventilation, scoliosis, and ectopia lentis should be monitored. In late-stage forms, a diet restricted in protein, methionine, and cysteine has been tested, with benefits limited to isolated cases and always under metabolic supervision. Fosdenopterin, indicated for molybdenum cofactor deficiency type A, does not correct the SUOX defect. Genetic counseling allows for carrier testing and prenatal or preimplantation diagnosis.
Genes analyzed
Bibliography
Sankaran BP, Nagappa M, Bharath RD, Taly AB. Isolated Sulfite Oxidase Deficiency. GeneReviews®. 2017.
Schwahn BC, van Spronsen FJ, Misko AL, et al. Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. J Inherit Metab Dis. 2024;47(4):598-623.
Göde L, Zielonka M, Garbade SF, Posset R. Ultra-orphan diseases: A cross-sectional quantitative analysis of the natural history of isolated sulfite oxidase deficiency. PLoS One. 2025;20(5):e0323043.
Li JT, et al. Mutation analysis of SUOX in isolated sulfite oxidase deficiency with ectopia lentis as the presenting feature: insights into genotype-phenotype correlation. Orphanet J Rare Dis. 2022;17:385.
